Novanta

Novanta, Inc. engages in the provision of core technology solutions to healthcare and advanced industrial original equipment manufacturers. It operates through the following segments: Photonics, Vision, and Precision Motion. The Photonics segment designs, manufactures, and markets photonics-based solutions, including laser scanning and laser beam delivery, CO2 laser, continuous wave and ultrafast laser, and optical light engine products. The Vision segment offers a range of medical grade technologies, including medical insufflators, pumps and related disposables, surgical displays and operating room integration technologies, optical data collection and machine vision technologies, radio frequency identification technologies, thermal printers, spectrometry technologies, and embedded touch screen solutions. The Precision Motion segment includes optical encoders, precision motor and motion control technology, air bearing spindles, and precision machined components to customers. The company was founded in 1968 and is headquartered in Bedford, MA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Novanta achieves record-breaking 2022 results, eyes growth opportunities

Novanta's strong financial performance in 2022, driven by record sales and profitability, positions the company for continued success.
While facing challenges such as margin pressures and operational disruptions, Novanta's strategic strengths in medical markets and growth opportunities in new product development pave the way for future growth.
With a focus on efficiency, innovation, and market diversification, Novanta is poised to capitalize on growth prospects in 2023 and beyond.
Overall, Novanta's robust performance, strategic initiatives, and financial stability underscore its resilience and potential for sustained growth in the coming years.

Novanta excels in Q1 with strong medical market growth

Novanta's Q1 performance showcased robust revenue growth, particularly in medical markets and North America. The company's strategic focus on new products and margin expansion positions it well for future success despite challenges in certain regions and segments.

Novanta excels in Q2 2023, eyes growth amid market challenges

Novanta's Q2 performance was robust, driven by strong sales in medical markets and strategic growth initiatives.
Challenges include declines in microelectronics and China market, but opportunities lie in new product launches and recovery expectations.
The company's focus on innovation, backlog reduction, and margin expansion positions it well for future growth.
Overall, Novanta exceeded expectations for margins and profits, with a positive outlook for 2024.

Novanta reports solid Q3 performance, eyes new product supercycle

Novanta delivered a strong Q3 performance, exceeding expectations in margins, profit, and cash flow.
The company remains confident in its long-term outlook, focusing on innovation and upcoming product launches.
Despite short-term challenges, Novanta is committed to executing its growth strategy and expanding gross margins.

Novanta reports record revenue in 2023, eyes growth in medical markets

Novanta delivered a solid performance in 2023, achieving record revenue, gross margin expansion, and profit despite market challenges.
The company's focus on new product launches, intelligent subsystems, and growth in medical solutions segment positions it for continued success in 2024.
Challenges from the macroeconomic environment and product ramp downs need to be addressed to ensure sustained growth and profitability.
Opportunities from acquisitions, new product launches, and revenue streams in medical markets offer avenues for future growth and cash flow.

Novanta reports solid Q2 performance, eyes growth through new products

Novanta's Q2 2024 earnings call showcased strong financial performance and strategic priorities for growth.
While facing challenges in certain markets, the company's focus on new products and margin expansion bodes well for the future.
Analysts are keen on revenue drivers, margin expansion, and segment performance as key areas of interest.

Novanta reports solid Q3 earnings, eyes growth amidst short-term challenges

Novanta's Q3 2024 performance reflects steady revenue growth and improved profitability, supported by strong bookings and new product revenue confirmations.
While facing short-term challenges in Q4 2024, the company remains optimistic about robust business growth in 2025, emphasizing new product launches and margin expansion.
Guidance for Q4 2024 and full year 2024 indicates a strategic focus on organic growth, margin improvement, and acquisitions to drive long-term value creation.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Novanta Inc. (NOVT) Q4 2023 Earnings Call Transcript

Novanta (NOVT) came out with quarterly earnings of $0.63 per share, in line with the Zacks Consensus Estimate. This compares to earnings of $0.75 per share a year ago.

Novanta (NOVT) Meets Q4 Earnings Estimates

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the fourth quarter and full year 2023. Financial Highlights Three Months Ended December 31,     Year Ended December 31,   (In millions, except per share amounts) 2023     2022     2023     2022   GAAP                               Revenue $ 211.6     $ 218.4     $ 881.7     $ 860.9.

Novanta Announces Financial Results for the Fourth Quarter and Full Year 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its fourth quarter and full year 2023 results on Wednesday, February 28, 2024. The Company will host a conference call on Wednesday, February 28, 2024, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call.

Novanta Inc. Schedules Earnings Release and Conference Call for Wednesday, February 28, 2024

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has completed the acquisition of Motion Solutions. “Motion Solutions is an excellent strategic fit to Novanta. Motion Solutions offers high-precision, customized precision motion subsystems and components to market-leading OEMs, largely centered on medical and life sciences applications. They a.

Novanta completes acquisition of Motion Solutions

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, Chuck Ravetto, Group President, and Ray Nash, Vice President, Corporate Finance, are scheduled to present at the CJS Securities 24th Annual New Ideas for the New Year Investor Conference on Wednesday, January 10, 2024, which is being held virtually. About Novanta Novant.

Novanta to Present at the CJS Securities 24th Annual New Ideas for the New Year Investor Conference on Wednesday, January 10, 2024

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the J.P. Morgan 42nd Annual Healthcare Conference on Wednesday, January 10, 2024, in San Francisco, California. About Novanta Novanta is a leading global supplier of core technology s.

Novanta to Present at the J.P. Morgan 42nd Annual Healthcare Conference on Wednesday, January 10, 2024

Align Technology

Allstate

Chewy

Dynatrace Inc

DoubleVerify Holdings

Fiserv

Five Below

Fusion Pharmaceuticals

Hologic

Since market valuations are always changing, along with outlooks for corporate revenue and earnings, any list of favored stocks is only a snapshot. Repeating the same analysis in the near term might lead to an entirely different list of compelling names.

10 ‘better values' in the stock market, selected for the next two years

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that it has entered into a definitive agreement to acquire Motion Solutions, a leading provider of highly engineered integrated solutions, for cash consideration of $189 million, subject to customary purchase price adjustments and closing conditions, including applicable regulatory approvals. Motion So.

Novanta announces agreement to acquire Motion Solutions

Novanta, Inc. (NASDAQ:NOVT ) Q3 2023 Earnings Conference Call November 7, 2023 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chair and Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Operator Good morning. My name is Andrea, and I will be your conference operator today.

Novanta, Inc. (NOVT) Q3 2023 Earnings Call Transcript

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the third quarter 2023. Financial Highlights Three Months Ended   (In millions, except per share amounts) September 29,     September 30,     2023     2022   GAAP               Revenue $ 221.5     $ 223.0   Operating Income $ 30.3     $ 28.7   Consolidated Net Income $ 21.2     $ 2.

Novanta Announces Financial Results for the Third Quarter 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the Baird 2023 Global Industrial Conference on Wednesday, November 8, 2023, in Chicago, Illinois. About Novanta Novanta is a leading global supplier of core technology solutions that.

Novanta to Present at the Baird 2023 Global Industrial Conference on Wednesday, November 8, 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its third quarter 2023 results on Tuesday, November 7, 2023. The Company will host a conference call on Tuesday, November 7, 2023, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed onli.

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, November 7, 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at Baird's 2023 Global Healthcare Conference on Wednesday, September 13, 2023, in New York, New York. About Novanta Novanta is a leading global supplier of core technology solutions that.

Novanta to Present at Baird's 2023 Global Healthcare Conference on Wednesday, September 13, 2023

Novanta (NOVT) came out with quarterly earnings of $0.80 per share, beating the Zacks Consensus Estimate of $0.72 per share. This compares to earnings of $0.78 per share a year ago.

Novanta (NOVT) Beats Q2 Earnings and Revenue Estimates

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the second quarter 2023. Financial Highlights Three Months Ended   (In millions, except per share amounts) June 30,     July 1,     2023     2022   GAAP               Revenue $ 229.5     $ 215.4   Operating Income $ 32.2     $ 23.3   Consolidated Net Income $ 20.9     $ 17.5   Dilu.

Novanta Announces Financial Results for the Second Quarter 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that the Company has received a Silver rating from EcoVadis for its sustainability practices. EcoVadis is an internationally recognized sustainability rating agency. Their Silver rating for Novanta places the Company in the top 25% of rated companies within Novanta's industry sector and was based on Ec.

Novanta receives Silver rating from EcoVadis

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, will release its second quarter 2023 results on Tuesday, August 8, 2023. The Company will host a conference call on Tuesday, August 8, 2023, at 10:00 a.m. ET to discuss these results. To access the call, please dial (888) 346-3959 before the scheduled conference call time. Alternatively, the conference call can be accessed online.

Novanta Inc. Schedules Earnings Release and Conference Call for Tuesday, August 8, 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Robert Buckley, Chief Financial Officer, is scheduled to present at the CJS Securities 23rd Annual New Ideas Summer Conference on Tuesday, July 11, 2023, in White Plains, New York. About Novanta Novanta is a leading global supplier of core technology solutions that give medical and advanced industrial original.

Novanta to Present at the CJS Securities 23rd Annual New Ideas Summer Conference on Tuesday, July 11, 2023

Does Novanta (NOVT) have what it takes to be a top stock pick for momentum investors? Let's find out.

What Makes Novanta (NOVT) a Strong Momentum Stock: Buy Now?

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at Baird's 2023 Global Consumer, Technology & Services Conference on Wednesday, June 7, 2023, in New York, NY. About Novanta Novanta is a leading global supplier of core technology s.

Novanta to Present at Baird's 2023 Global Consumer, Technology & Services Conference on Wednesday, June 7, 2023

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (the "Company"), a trusted technology partner to medical and advanced technology equipment manufacturers, announced today that Matthijs Glastra, Chair & Chief Executive Officer, and Robert Buckley, Chief Financial Officer, are scheduled to present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023, in Chicago, IL. About Novanta Novanta is a leading global supplier of core technology solutions that gi.

Novanta to Present at the William Blair 43rd Annual Growth Stock Conference on Tuesday, June 6, 2023

Novanta Inc. (NASDAQ:NOVT ) Q1 2023 Earnings Conference Call May 9, 2023 10:00 AM ET Company Participants Ray Nash - Corporate Finance Leader Matthijs Glastra - Chairman & Chief Executive Officer Robert Buckley - Chief Financial Officer Conference Call Participants Lee Jagoda - CJS Securities Brian Drab - William Blair Robert Mason - Baird Operator Good morning. My name is Andrea and I will be your conference operator today.

Novanta Inc. (NOVT) Q1 2023 Earnings Call Transcript

Novanta (NOVT) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.

Novanta (NOVT) is on the Move, Here's Why the Trend Could be Sustainable

BEDFORD, Mass.--(BUSINESS WIRE)--Novanta Inc. (Nasdaq: NOVT) (“Novanta” or the “Company”), a trusted technology partner to medical and advanced technology equipment manufacturers, today reported financial results for the first quarter 2023. Financial Highlights Three Months Ended   (In millions, except per share amounts) March 31,     April 1,     2023     2022   GAAP               Revenue $ 219.1     $ 204.2   Operating Income $ 26.3     $ 24.3   Consolidated Net Income $ 18.3     $ 18.8   Dil.

News for Novanta Stock (NOVT)